23 series
Export
<<< of 2>>>
Accession Title Series type(s) Organism(s) Samples GDS Supplementary Contact Release date
Remove filtersFilter Remove filterShawn Anderson
GSE34649
Integrated genome and transcriptome sequencing identifies a novel case of hybrid and aggressive prostate cancer
5 Shawn Anderson Dec 22, 2011
GSE41188
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development (aCGH)
24 Shawn Anderson Jan 12, 2013
GSE41192
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development (expression)
32 Shawn Anderson Jan 12, 2013
GSE41193
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development
56 Shawn Anderson Jan 12, 2013
GSE44319
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity cancer.
52 Shawn Anderson Feb 15, 2013
GSE48667
Enhancement by Aneustat (OMN54) of docetaxel anticancer activity in a patient-derived prostate cancer tissue xenograft model
8 Shawn Anderson Oct 23, 2014
GSE49342
GATA2 as a potential prostate cancer metastasis-driving gene
8 Shawn Anderson Jan 20, 2014
GSE55016
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
28 Shawn Anderson Jul 21, 2014
GSE55345
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
6 Shawn Anderson Jan 01, 2015
GSE59984
The placental gene PEG10 promotes progression of neuroendocrine prostate cancer [Expression]
14 Shawn Anderson Jan 05, 2015
GSE59985
The placental gene PEG10 promotes progression of neuroendocrine prostate cancer [aCGH]
6 Shawn Anderson Jan 05, 2015
GSE59986
The placental gene PEG10 promotes progression of neuroendocrine prostate cancer
20 Shawn Anderson Jan 05, 2015
GSE61134
Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance and response in castration-resistant prostate cancer
62 Shawn Anderson Mar 09, 2015
GSE61214
Identification of DEK as a potential therapeutic target for Neuroendocrine prostate cancer
4 Shawn Anderson Jan 15, 2015
GSE66850
Therapy-Induced Developmental Reprogramming of Prostate Cancer Cells and Acquired Resistance [Dataset 1]
24 Shawn Anderson Mar 11, 2016
GSE66851
Therapy-Induced Developmental Reprogramming of Prostate Cancer Cells and Acquired Resistance [Dataset 2]
6 Shawn Anderson Mar 11, 2016
GSE66852
Therapy-Induced Developmental Reprogramming of Prostate Cancer Cells and Acquired Resistance
30 Shawn Anderson Mar 11, 2016
GSE67256
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis
6 Shawn Anderson Mar 01, 2016
GSE77516
BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer
8 Shawn Anderson Feb 04, 2016
GSE78245
The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells
12 Shawn Anderson Feb 24, 2016